摘要 |
<p>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation: (I).</p> |
申请人 |
CANCER RESEARCH TECHNOLOGY LIMITED;COLLINS, IAN;READER, JOHN, CHARLES;WILLIAMS, DAVID, HUGH;KLAIR, SUKHBINDER, SINGH;SCANLON, JANE, ELIZABETH;PITON, NELLY;CHERRY, MICHAEL |
发明人 |
COLLINS, IAN;READER, JOHN, CHARLES;WILLIAMS, DAVID, HUGH;KLAIR, SUKHBINDER, SINGH;SCANLON, JANE, ELIZABETH;PITON, NELLY;CHERRY, MICHAEL |